Stockreport

Celsion Announces Highly Encouraging Initial Clinical Results from the Phase I Portion of the Phase I/II OVATION 2 Study with GEN-1 in Patients with Advanced Ovarian Cancer

Celsion Corporation  (CLSN) 
Last celsion corporation earnings: 11/14 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.celsion.com/investor-relations
PDF  R0 (Complete) Surgical Resection Rates for Patients Randomized to GEN-1 Treatment Arm Compare Favorably to Patients Receiving Neoadjuvant Chemotherapy Only Company [Read more]